Introduction
Bispecific antibody formats
Fc containing architecture
Fc containing | Fc less | |
---|---|---|
Representative platform | Duobody, CrossMab, FIT-Ig | BiTE, DART, TandAb |
Representative drug | Catumaxomab | Bilncyto |
Advantages | CMC: Good solubility and stability Curative effect: Induce secondary immune functions (ADCC, ADCP and CDC); long in vivo half-life | CMC: Small size, high yield, easy to produce Curative effect: Low immunogenicity; Fewer side-effects; Better tissue-penetrating capacity; For CD3 × antigen format, T cell mediated tumor cell killing is better than which Fc mediated |
Disadvantages | Mis-paring and purification problems; relatively poor permeability of tumor tissue | Requires specific purification technology; require half-life extension or frequent dosing |
Fc less architecture
Dual TAAs targeting BsAbs
Antibody Name | Sponsor | Targets | Format | Diseases | Clinical studies |
---|---|---|---|---|---|
Zenocutuzumab, MCLA-128 PB4188 | Merus | HER2 × HER3 | Fab × Fab-Fc, IgG1, 1 + 1 | Solid tumors harboring NRG1 fusion NSCLC harboring NRG1 fusion Pancreatic cancer Harboring NRG1 fusion | Phase II (NCT03321981) |
OXS-1550, DT2219ARL | GT biopharma | CD19 × CD22 | scFv × scFv, 1 + 1 | Refractory B-lineage leukemia Relapsed B-lineage leukemia | Phase I/II (NCT02370160) |
EMB01 | EpimAb Biotherapeutics | EGFR × c-MET | Fab × Fab-Fc, IgG1, 2 + 2 | Neoplasms Neoplasm metastasis Non-small-cell lung cancer | Phase I/II (NCT03797391) |
JNJ-61186372 | Janssen | EGFR × c-MET | Fab × Fab-Fc, IgG1, 1 + 1 | Non-small-cell lung cancer | Phase I (NCT02609776 and NCT04077463) |
TG-1801, NI-1701 | TG Therapeutics | CD47 × CD19 | Fab × Fab-Fc, IgG1, 1 + 1 | B cell lymphoma | Phase I (NCT03804996) |
IBI322 | Innovent biologics | CD47 × PDL-1 | Undisclosed | Advanced malignancies | Phase I (NCT04338659 and NCT04328831) |
MCLA-158 | Merus | EGFR × LGR5 | Fab × Fab-Fc, IgG1, 1 + 1 | Advanced/metastatic solid tumors Colorectal Cancer | Phase I (NCT03526835) |
IMM0306 | ImmuneOnco | CD20 × CD47 | Fab × Ligand-Fc, IgG1, 2 + 2 | Non-hodgkin lymphoma | Phase I (CTR20192612) |
RO6874813 (RO7386) | Roche | DR5 × FAP | Fab × Fab-Fc, IgG1, 2 + 2 | Advanced and/or metastatic solid tumors | Phase I (NCT02558140) |